Furthermore, high expressions of activated inflammasomes, IL-1β and IL-18, are also used as independent predictors of poor prognoses in ccRCC patients, while the tumor promoting cytokine, IL-6, has been implicated in the progression of RCC (33, 34). The gene discussed is IL18; the disease is neoplasm.